伊立替康联合顺铂治疗晚期非小细胞肺癌的临床观察

目的观察伊立替康(开普拓)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法经病理学或细胞学确诊的初治晚期NSCLC患者15例,男性10例,女性5例,中位年龄47岁(32～58岁),KPS评分>70。接受顺铂80mg/m2联合伊立替康60mg/m2,第l、8、15天静脉滴注,每4周重复。至少2周期后评价疗效。结果全组PR4例,SD9例,PD2例,总有效率26.7%。中位生存时间11个月,1年生存为率46.7%(7/15)。主要不良反应为延迟性腹泻和粒细胞减少。结论伊立替康联合顺铂治疗晚期NSCLC疗效确切,不良反应发生率低,耐受性较好。

Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer

Objective To evaluate the efficacy and adverse effects of irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Fifteen patients(10 males and 5 females) aged from 32 to 58 years(median age of 47 years) with KPS>70 and the diagnosis of advanced NSCLC by pathology or cytology were treated with cisplatin 80 mg/m2 plus irinotecan 60 mg/m2 by intravenous infusion on 1,8,15 days,and the treatment was repeated every 4 weeks.After treatment for at least 2 cycles,t...